M464
Based on 1 Customer Validation
M464, a non-steroidal anti-inflammatory compound, is a potent and orally active NLRP3 inflammasome inhibitor. M464 inhibits pyroptosis and hinders the activation of downstream Caspase-1 expression and the release of IL-1β by impeding ASC oligomerisation and curtailing ROS production. M464 exhibits protective effects against acute lung and liver injury in mice. M464 can be used for the research of NLRP3-related inflammatory diseases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.58%
- Fòrmula: C23H28O4S3
- Peso molecular:464.66
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Ver todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
NLRP3 inflammasome |
In Vitro
M464 (3-12 μM) inhibits the expression of marker proteins associated with NLRP3 inflammasome activation (IL-1β and Caspase-1), and restrains the production of intracellular ROS and the formation of ASC oligomers in J774A.1 and THP-1 cells[1].
M464 (3-12 μM; 1 h) inhibits pyroptosis in macrophages triggered by the NLRP3 inflammasome stimulator in J774A.1 and THP-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
M464 (15, 30, 60 mg/kg; i.g.; single dose; 1 hour before LPS injection) mitigates LPS and D-GalN-induced acute liver injury in mice by inhibiting NLRP3 inflammasome activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male KM mice (42-56 days old) intraperitoneally injected with LPS (10 mg/kg)[1]
-
Dosage:15, 30, 60 mg/kg
-
Administration:i.g.; single dose; 1 hour before LPS injection
-
Result:Dose-dependently reduced the pathological scores of lung injury.
Significantly improved the lung tissue damage in mice.
Inhibited the lung wet/dry (W/D) weight ratio and significantly improved pulmonary edema in mice.
Significantly reduced the levels of mature IL-1β and Caspase-1.
-
Animal Model:Male KM mice (42-56 days old) intraperitoneally injected with LPS (50 μg/kg) and D-GalN (800 mg/kg)[1]
-
Dosage:15, 30, 60 mg/kg
-
Administration:i.g.; 1 hour before LPS injection
-
Result:Reversed the LPS and D-GalN induced increase of the liver-to-body weight ratio.
Markedly attenuated LPS/D-GalN-induced liver injury in mice.
Exhibited dose-dependent suppression of serum levels of AST and ALT.
Effectively suppressed the mature IL-1β release and Caspase-1 production in a dose-dependent manner.
Effectively reversed the LPS/D-GalN-induced reduction in SOD content and increase in MDA level.
Chemical Information
-
Appearance Solid
-
Peso molecular 464.66
-
Fòrmula C23H28O4S3
-
Color Orange to red
-
SMILES
CC1CC(OC(CCC(OC2=CC=C(C3=CC(SS3)=S)C=C2)=O)=O)C(C(C)C)CC1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocolo
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)